Affymetrix announced that it has signed a contract with UK Biobank to genotype 500,000 DNA samples donated by UK residents as part of a prospective epidemiological study of complex diseases that are of great relevance to public health. Affymetrix’ Axiom Genotyping Solution will be used to generate billions of high-quality genotypes which will provide UK Biobank and the research community with valuable insight to genetic factors underlying human diseases for improved prevention, diagnosis, and treatment of conditions such as heart disease, cancer, and diabetes. Affymetrix expects to begin delivering data for the study towards the end of 2013. Affymetrix does not expect revenue from this contract to have a material impact in 2013, as it will start to recognize revenue in the latter part of this year, with the majority of the revenue expected to be recognized in 2014.
- Disease & Medical Conditions
- UK Biobank